

## REMARKS/ARGUMENTS

### Restriction Requirement

The Examiner has required restriction to one of the following inventions:

Group I. Claims 1-9 (in part), drawn to an isolated polynucleotide, recombinant expression vector, host cell, and a process for producing polypeptide. Further restriction to one SEQ ID NO required.

Group II. Claims 10-12 and 15-17 (in part), drawn to polypeptide and a composition comprising said polypeptide. Further restriction to one SEQ ID NO required.

Group III. Claims 13-14 and 15-17 (in part), drawn to an antibody and a composition comprising said antibody. Further restriction to one SEQ ID NO required.

Group IV. Claim 18 (in part), drawn to an article manufacture. Further restriction to one SEQ ID NO required.

Group V. Claim 19 (in part), drawn to a method for treating psoriasis using PRO polypeptide or antagonist or antibody. Further restriction to one SEQ ID NO required.

Group VI. Claim 20 (in part), drawn to a method for determining the presence of PRO polypeptide in a sample using anti-PRO antibody. Further restriction to one SEQ ID NO required.

Group VII. Claim 21 (in part), drawn to a method for diagnosing psoriasis using gene encoding PRO polypeptide.. Further restriction to one SEQ ID NO required.

Group VIII. Claim 22 (in part), drawn to a method for diagnosing psoriasis using anti-PRO antibody. Further restriction to one SEQ ID NO required.

Group IX. Claim 23 (in part), drawn to a method for identifying a compound that inhibits the activity of PRO polypeptide. Further restriction to one SEQ ID NO required.

Group X. Claims 24-25 (in part), drawn to a method for identifying a compound that inhibits the expression of gene encoding PRO polypeptide. Further restriction to one SEQ ID NO required.

Group XI. Claim 23 (in part), drawn to a method for identifying a compound that mimics the activity of PRO polypeptide. Further restriction to one SEQ ID NO required.

Applicants elect Group III, Claims 13-14 and 15-17 (in part), drawn to an antibody and a composition comprising said antibody. Applicants further elect SEQ ID NO:20 for the elected claims.

**CONCLUSION**

In conclusion, the present application is believed to be in *prima facie* condition for allowance, and an early action to that effect is respectfully solicited. Should there be any further issues outstanding, the Examiner is invited to contact the undersigned agent at the telephone number shown below.

Please charge any additional fees, including fees for additional extension of time, or credit overpayment to Deposit Account No. 08-1641 (referencing Attorney's Docket No. 39766-0266 R1). Please direct any calls in connection with this application to the undersigned at the number provided below.

Respectfully Submitted,

By: \_\_\_\_\_  
Panpan Gao (Reg. No. 43,626)

Date: November 2, 2007  
  
HELLER EHRMAN LLP  
275 Middlefield Road  
Menlo Park, California 94025  
Telephone: (650) 324-7000  
Facsimile: (650) 324-0638

SV 2313203 v1  
(39766.0266)